Koligo Therapeutics, Inc. — Form D
Koligo Therapeutics, Inc. of New Albany, IN, a company, filed a Form D exempt-offering notice with the SEC on 2020-10-07. The offering totals $1.6M, of which $1.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-10-07
- Form: D
- Accession: 0001707597-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $1.6M
- Amount sold: $1.6M
- Minimum investment: $20K
- Investors: 2
- Date of first sale: 2020-09-25
- Security types: equity
- Revenue range: $1,000,001 - $5,000,000
- SEC file number: 021-377285
Issuer
- Name: Koligo Therapeutics, Inc.
- CIK: 0001707597
- Entity type: Corporation
- Jurisdiction: KENTUCKY
- Incorporated: 2016
- Address: 2113 State Street, New Albany, IN, 47150
- Phone: 5022654830
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Matthew Lehman | Executive Officer | FARGO, ND |
| Michael B Hughes | Director | Louisville, KY |
| Michael B Hughes | Executive Officer | Louisville, KY |
| Stuart B Williams | Director | Louisville, KY |
| Stuart B Williams | Executive Officer | Louisville, KY |
| Matthew B Lehman | Director | Louisville, KY |
| Matthew B Lehman | Executive Officer | Louisville, KY |
| Balamurugan B Appakalai | Director | Louisville, KY |
| Balamurugan B Appakalai | Executive Officer | Louisville, KY |
| David B Blanford | Director | Louisville, KY |
| David B Blanford | Executive Officer | Louisville, KY |
Other filings by this issuer (2)
More